1XT Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)1.67K
Market Cap
€15.90M
Enterprise Value€117.53M
Total Cash (Recent Filing)€23.21M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Aug 28, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding861,266,850
10 Day Avg. Volume5,000
30 Day Avg. Volume1,666
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)-37.15
Price to Sales (P/S)85.84
P/FCF Ratio-4.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)€1.09M
Bulls Say, Bears Say
Bulls Say
Proprietary ITGA10 PlatformXintela’s patented ITGA10 platform is a durable competitive asset allowing multiple program paths (regenerative and oncology). Platform IP supports out-licensing, co-development and modular product development, increasing long-term optionality and partner appeal independent of short-term trial outcomes.
Low Leverage (no Debt)Zero debt reduces fixed financial obligations and interest expense, giving strategic flexibility for R&D-heavy development cycles. For an early-stage biotech this lowers immediate refinancing pressure and preserves capacity to structure partner deals or equity raises under less strained liquidity conditions.
Positive Gross Profit (2024–2025)Achieving positive gross profit indicates that core development or early commercial activities can cover direct costs, implying product economics may scale favorably. If SG&A and development investment are controlled, this structural margin improvement can underpin a path toward sustainable profitability with successful commercialization or partnerships.
Bears Say
Sustained Cash BurnPersistent large negative operating cash flows indicate ongoing financing dependency to fund trials and operations. This elevates dilution and execution risk because repeated capital raises may be required, which can shift focus from long-term value creation to short-term financing and slow program advancement.
Negative Shareholders' EquityNegative equity materially weakens balance-sheet resilience and limits financial flexibility. It restricts borrowing options despite zero debt, can complicate partner negotiations or licensing terms, and signals that past funding has not translated into retained capital, raising structural financing and governance concerns.
Volatile And Declining RevenueLarge, inconsistent revenue swings and recent declines show limited commercial traction and unpredictable cash inflows. For a company reliant on milestone/license income, this revenue volatility undermines planning, increases reliance on equity financing, and complicates sustaining long-term development programs.
Xintela AB News
1XT FAQ
What was Xintela AB’s price range in the past 12 months?
Xintela AB lowest stock price was <€0.01 and its highest was €0.05 in the past 12 months.
What is Xintela AB’s market cap?
Xintela AB’s market cap is €15.90M.
When is Xintela AB’s upcoming earnings report date?
Xintela AB’s upcoming earnings report date is Aug 28, 2026 which is in 55 days.
How were Xintela AB’s earnings last quarter?
Xintela AB released its earnings results on May 29, 2026. The company reported >-€0.001 earnings per share for the quarter, the consensus estimate of >-€0.001 by €0.
Is Xintela AB overvalued?
According to Wall Street analysts Xintela AB’s price is currently Overvalued.
Does Xintela AB pay dividends?
Xintela AB does not currently pay dividends.
What is Xintela AB’s EPS estimate?
Xintela AB’s EPS estimate is >-0.01.
How many shares outstanding does Xintela AB have?
Xintela AB has 861,266,850 shares outstanding.
What happened to Xintela AB’s price movement after its last earnings report?
Xintela AB reported an EPS of >-€0.001 in its last earnings report, expectations of >-€0.001. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Xintela AB?
Currently, no hedge funds are holding shares in DE:1XT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xintela AB
Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden, concentrates its efforts on two key areas: regenerative medicine, particularly for cartilage repair, and oncology, with a focus on brain tumors. Central to their work is XINMARK, a patented marker technology used to accurately identify and isolate specific stem cells that can develop into cartilage cells. Their product portfolio includes XSTEM, a stem cell-based therapy undergoing clinical trials for treating knee osteoarthritis and persistent leg ulcers. They also offer EQSTEM, another stem cell product, for managing joint conditions in horses. In oncology, Xintela is engaged in the preclinical development of therapeutic antibodies designed to combat aggressive cancers like glioblastoma, a severe brain tumor, and triple-negative breast cancer.
Technical Analysis
Isofol Medical AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―